Guide De Référence Sur L'application De La Tps Et De La Tvq Pour Les Agences

Total Page:16

File Type:pdf, Size:1020Kb

Guide De Référence Sur L'application De La Tps Et De La Tvq Pour Les Agences GUIDE DE RÉFÉRENCE SUR L’APPLICATION DE LA TPS ET DE LA TVQ POUR LES AGENCES ET LES ÉTABLISSEMENTS PUBLICS DE LA SANTÉ ET DES SERVICES SOCIAUX RÉDIGÉ PAR RAYMOND CHABOT GRANT THORNTON EN COLLABORATION AVEC LE MINISTÈRE DE LA SANTÉ ET DES SERVICES SOCIAUX JANVIER 2006 Guide de référence sur la TPS/TVQ – Janvier 2006 Élaboration du guide Le présent guide de référence a été rédigé par Mme Guylaine Dallaire, c.a., M.Fisc., asso- ciée, et M. Sylvain Thibeault, LL.B., M.Fisc., directeur principal, de Raymond Chabot Grant Thornton S.E.N.C.R.L. en collaboration avec M. Laurent Bourque, c.a. et M. Pierre Martin, c.a. du Service des normes et pratiques de gestion du ministère de la Santé et des Services sociaux. Ce guide a été élaboré pour en permettre facilement la mise à jour, le cas échéant. Guide de référence sur la TPS/TVQ – Janvier 2006 Exonération de responsabilité et reproduction Exonération de responsabilité Bien que ce document dresse un portrait fidèle de l'impact des taxes à la consommation pour les organismes évoluant dans le réseau québécois de la santé et des services sociaux, il ne représente pas une analyse exhaustive du droit fiscal et de la jurisprudence associée et ne saurait se substituer à la Loi sur la taxe d'accise, à la Loi sur la taxe de vente du Québec ou aux règlements correspondants. Ce document fiscal a été rédigé par Raymond Chabot Grant Thornton S.E.N.C.R.L. en colla- boration avec le ministère de la Santé et des Services sociaux pour le bénéfice des établissements et des agences de santé et de services sociaux évoluant dans le réseau québécois de la santé et des services sociaux. Il est entendu que les auteurs, les collaborateurs ainsi que leurs employeurs ne sont pas responsables des conséquences de quelque décision que ce soit fondée sur l'information contenue dans le présent Guide, ou de quelque erreur ou omission que ce soit. Le lecteur ne devrait prendre aucune décision sans avoir consulté un conseiller professionnel. Reproduction Toute reproduction totale ou partielle de ce document est autorisée à condition que la source soit mentionnée. Guide de référence sur la TPS/TVQ – Janvier 2006 Table des matières Page LISTE DES ABRÉVIATIONS .................................................................................... 1 INTRODUCTION..................................................................................................... 3 1. LES ACTEURS ............................................................................................ 5 1.1 Le réseau québécois de la santé et des services sociaux selon la L.S.S.S.S......................................................................................... 5 1.2 Les acteurs de la santé et des services sociaux selon les dispositions législatives en matière de TPS/TVQ.............................. 7 1.2.1 Qualification aux fins des exonérations prévues en TPS/TVQ des établissements du réseau québécois de la santé et des services sociaux et des agences .......................................................... 9 1.2.2 Qualification aux fins des remboursements partiels de TPS/TVQ des établissements du réseau québécois de la santé et des services sociaux .................................................................... 10 1.3 Distinctions entre un organisme de bienfaisance et un organisme sans but lucratif .............................................................................. 11 2. L'INSCRIPTION ET LA DÉCLARATION ........................................................ 13 2.1 Inscription au registre des taxes ...................................................... 13 2.1.1 Inscription obligatoire............................................................ 13 2.1.2 Seuil du petit fournisseur ........................................................ 13 2.1.2.1 Organismes de bienfaisance et institutions publiques............................................................... 13 2.1.2.2 Autres organismes du secteur public...................... 15 2.1.2.3 Établissements privés............................................ 15 2.1.3 Inscription facultative ............................................................ 16 2.1.4 Nouvel inscrit........................................................................ 16 2.1.5 Cessation de l’inscription ....................................................... 17 2.2 Exercice et périodes de déclaration ................................................. 17 2.2.1 Règle générale...................................................................... 17 2.2.2 Inscrits................................................................................. 18 3. LES FOURNITURES ET L'ASSUJETTISSEMENT DES TRANSACTIONS........ 19 3.1 Type de fournitures ......................................................................... 19 3.2 Fournitures aux gouvernements....................................................... 20 3.3 Indication de la taxe ........................................................................ 20 3.4 Assujettissement............................................................................. 20 3.4.1 Contrepartie ......................................................................... 20 3.4.2 Moment de l’assujettissement ................................................ 21 Guide de référence sur la TPS/TVQ – Janvier 2006 Page 3.4.3 Contrepartie partielle ............................................................. 22 3.4.4 Fourniture terminée................................................................ 22 3.4.5 Fourniture continue ................................................................ 23 3.4.6 Vente d’un immeuble ............................................................. 23 3.4.7 Contrepartie invérifiable ......................................................... 23 3.4.8 Fourniture combinée .............................................................. 24 3.4.9 Arrhes (dépôt) ....................................................................... 24 4. LES REVENUS EXONÉRÉS .......................................................................... 27 4.1 Exonérations applicables aux organismes de bienfaisance................ 28 4.1.1 Exonération générale et exceptions.......................................... 28 4.1.2 Fourniture d’un droit d’entrée à une activité de financement ....... 32 4.1.3 Fourniture par vente d’un bien meuble ou d’un service dans le cadre d’activités de financement ............................................. 32 4.1.4 Fourniture d’aliments ou de boissons aux aînés, aux personnes handicapées ou défavorisées................................................... 33 4.1.5 Fourniture de biens ou services effectuée à titre gratuit .............. 33 4.1.6 Fourniture d’un bien meuble corporel ou d’un service (coût direct) .................................................................................. 34 4.1.6.1 Organisme de bienfaisance inscrit à la TPS/TVQ..... 35 4.1.6.2 Organisme de bienfaisance non inscrit à la TPS/TVQ................................................................ 36 4.1.7 Fourniture d’aliments, de boissons ou d’un logement provisoire par un organisme de bienfaisance............................................ 37 4.1.8 Fourniture d’un droit d’entrée à un lieu de divertissement où l’activité principale consiste en des jeux de hasard.................... 37 4.2 Exonérations applicables aux institutions publiques ......................... 37 4.2.1 Exonération générale et exceptions.......................................... 37 4.2.2 Fourniture par une institution publique d’un droit d’entrée à une activité de financement .......................................................... 40 4.2.3 Fourniture par vente d’un bien meuble corporel ou d’un service par une institution publique – activité de financement................ 40 4.2.4 Fourniture par une institution publique du droit de jouer à un jeu de hasard.............................................................................. 40 4.3 Exonérations applicables aux organismes du secteur public (autres que des organismes de bienfaisance)............................................... 41 4.3.1 Fourniture par vente d’un bien meuble corporel par un organisme du secteur public ................................................... 41 4.3.2 Fourniture d’un droit d’entrée dans un lieu de divertissement où l’activité principale consiste en des jeux de hasard.................... 41 4.3.3 Fourniture du droit d’entrée dans un lieu de divertissement pour une contrepartie inférieure à un dollar ...................................... 42 4.3.4 Fourniture de biens ou services effectuée à titre gratuit .............. 42 4.3.5 Fourniture d’un droit d’adhésion à un programme de formation par un organisme du secteur public ......................................... 42 Guide de référence sur la TPS/TVQ – Janvier 2006 Page 4.3.6 Fourniture de services de pension et d’hébergement ou de loisirs par un organisme du secteur public......................................... 42 4.3.7 Fourniture d’aliments, de boissons ou de logement provisoire par un organisme du secteur public......................................... 43 4.3.8 Fourniture d’aliments ou de boissons par un organisme du secteur public ....................................................................... 43 4.3.9 Fourniture d’un droit d’adhésion à un organisme du secteur public .................................................................................. 43 4.3.10 Fourniture du droit d’être spectateur à un spectacle ou à un événement sportif ou compétitif .............................................
Recommended publications
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,124,126 B2 Bosse Et Al
    USOO81241.26B2 (12) United States Patent (10) Patent No.: US 8,124,126 B2 BOSse et al. (45) Date of Patent: Feb. 28, 2012 (54) PHARMACEUTICAL COMPOSITIONS (58) Field of Classification Search ........................ None See application file for complete search history. (75) Inventors: Paul Bosse, Charleston, SC (US); John Ameling, Cincinnati, OH (US); Bernard (56) References Cited Schachtel, Jupiter, FL (US); Ray Takigiku, Loveland, OH (US) U.S. PATENT DOCUMENTS 4,113,866 A 9, 1978 Lednicer et al. (73) Assignee: Charleston Laboratories, Inc., (Continued) Charleston, SC (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this CA 2665841 10/2007 patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 12/351,704 OTHER PUBLICATIONS Alexander, etal. Comparison ofondansetron and droperidol in reduc (22) Filed: Jan. 9, 2009 ing postoperative nausea and vomiting associated with patient-con trolled analgesia. Anaesthesia. Dec. 1995:50(12): 1086-8. (65) Prior Publication Data (Continued) US 2009/O175939 A1 Jul. 9, 2009 Primary Examiner — Susan Tran Related U.S. Application Data (74) Attorney, Agent, or Firm — Wilson Sonsini Goodrich & (60) Provisional application No. 61/020,139, filed on Jan. Rosati 9, 2008, provisional application No. 61/043,037, filed on Apr. 7, 2008, provisional application No. (57) ABSTRACT 61/060,758, filed on Jun. 11, 2008. Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including (51) Int. Cl. reducing or eliminating an adverse effect associated with the A6 IK9/20 (2006.01) analgesic. A6 IK9/24 (2006.01) (52) U.S.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter Et Al
    USOO9205048B2 (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter et al. (45) Date of Patent: *Dec. 8, 2015 (54) CONTROLLED RELEASE ANTIMICROBIAL (58) Field of Classification Search COMPOSITIONS AND METHODS FOR THE CPC A61 K9/0024; A61 K9/0046; A61K 31/497; TREATMENT OF OTC DSORDERS A61K 47/34 See application file for complete search history. (71) Applicants: Otonomy, Inc., San Diego, CA (US); The Regents of the University of California, Oakland, CA (US) (56) References Cited (72) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); U.S. PATENT DOCUMENTS Andrew M. Trammel, Olathe, KS (US); 4,188,373 A 2, 1980 Krezanoski Fabrice Piu, San Diego, CA (US); 4,478,822 A 10, 1984 Haslam et al. Qiang Ye, San Diego, CA (US); Luis A. 4,938,763. A 7, 1990 Dunn et al. Dellamary, San Marcos, CA (US); Carl 4,968,507 A 11/1990 Zentner et al. 5,033,252 A 7, 1991 Carter Lebel, Malibu, CA (US); Jeffrey P. 5,052,558 A 10, 1991 Carter Harris, La Jolla, CA (US) 5,292,516 A 3/1994 Viegas et al. 5,323,907 A 6/1994 Kalvelage (73) Assignees: OTONOMY, INC., San Diego, CA 5,324,519 A 6/1994 Dunn et al. (US): THE REGENTS OF THE 5,421,818 A 6/1995 Arenberg UNIVERSITY OF CALIFORNLA, 5,474,529 A 12/1995 Arenberg 5,476,446 A 12/1995 Arenberg Oakland, CA (US) 5,503,848 A 4/1996 Perbellini et al. 5,702,716 A 12/1997 Dunn et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al
    USO09526704B2 (12) United States Patent (10) Patent No.: US 9,526,704 B2 BOSse et al. (45) Date of Patent: *Dec. 27, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR A6IR 9/24 (2006.01) TREATING OR PREVENTING PAN A69/20 (2006.01) (52) U.S. Cl. (71) Applicant: LOCL Pharma, Inc., Las Vegas, NV CPC ............. A61K 9/209 (2013.01); A61 K9/2013 (US) (2013.01); A61 K9/2054 (2013.01); A61 K 3 1/167 (2013.01); A61K 31/485 (2013.01); (72) Inventors: Paul Bosse, Jupiter, FL (US); John A61K 3.1/5415 (2013.01) Ameling, Jupiter, FL (US); Bernard (58) Field of Classification Search Schachtel, Jupiter, FL (US); Ray CPC A61K 2300/00; A61K 31/167; A61K 31/485; Takigiku, Loveland, OH (US) A61K 3.1/5415: A61 K9/2054: A61 K 9/209 (73) Assignee: LOCL PHARMA, INC., Las Vegas, See application file for complete search history. NV (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,048,526 A 8/1962 Boswell This patent is Subject to a terminal dis- 3,108,046 A 10/1963 Harbit claimer. (Continued) (21) Appl. No.: 15/206.955 FOREIGN PATENT DOCUMENTS 1-1. CA 2262267 A1 8, 1999 (22) Filed: Jul. 11, 2016 DE 102005O13726 A1 9, 2006 (65) Prior Publication Data (Continued) US 2016/0317447 A1 Nov. 3, 2O16 OTHER PUBLICATIONS Related U.S. Application Data US 8.975,271, 03/2015, Oshlack et al.
    [Show full text]
  • Perspectives in Drug Discovery a Collection of Essays on the History and Development of Pharmaceutical Substances
    Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Artillerigatan 12 • SE-587 58 Linköping • Sweden E-mail: [email protected] Internet: www.rmv.se RMV-report 2010:1 ISSN 1103-7660 Copyright © 2010 National Board of Forensic Medicine and Professor Alan Wayne Jones Design and graphic original: Forma Viva, Linköping • Sweden Printed by Centraltryckeriet, Linköping • Sweden, October 2010 Contents Preface Introduction 1. The First Sedative Hypnotics . 13 2. The Barbiturates ......................... 19 3. The Benzodiazepines ..................... 25 4. Narcotic Analgesics . 31 5. Central Stimulant Amines . 39 6. The First Antidepressants .................. 45 7. Antipsychotic Medication ................. 51 8. Aspirin and Other NSAID .................. 59 9. General Anesthetics . 65 10. SSRI Antidepressants . 71 11. Histamine Antagonists .................... 79 12. Anticonvulsants ......................... 87
    [Show full text]
  • Wo 2009/132050 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132050 A2 (51) International Patent Classification: 61/101,1 12 29 September 2008 (29.09.2008) US A61K 39/395 (2006.01) A61K 47/34 (2006.01) 61/140,033 22 December 2008 (22. 12.2008) US A61P 27/16 (2006.01) A61K 9/06 (2006.01) 61/160,233 13 March 2009 (13.03.2009) US (21) International Application Number: (71) Applicants (for all designated States except US): OTON- PCT/US2009/041320 OMY, INC. [US/US]; 5626 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). THE REGENTS OF THE (22) International Filing Date: UNIVERSITY OF CALIFORNIA [US/US]; 1111 2 1 April 2009 (21 .04.2009) Franklin Street, 12th Floor, Oakland, CA 94607 (US). (25) Filing Language: English (72) Inventors; and (26) Publication Language: English (75) Inventors/Applicants (for US only): LICHTER, Jay [US/US]; P.O. Box 676244, Rancho Santa Fe, CA 92067 (30) Priority Data: (US). VOLLRATH, Benedikt [DE/US]; 4704 Niagara 61/046,543 2 1 April 2008 (21 .04.2008) US Avenue, San Diego, CA 92107 (US). TRAMMEL, An¬ 61/048,878 29 April 2008 (29.04.2008) US drew, M. [US/US]; 12485 South Alden Circle, Olathe, 61/127,7 13 14 May 2008 (14.05.2008) us KS 66062 (US). DURON, Sergio, G. [US/US]; 1605 61/055,625 23 May 2008 (23.05.2008) us Neale Street, San Diego, CA 92103 (US).
    [Show full text]
  • Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants
    Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants Author Sirdaarta, Joseph P Published 2016 Thesis Type Thesis (PhD Doctorate) School School of Natural Sciences DOI https://doi.org/10.25904/1912/1565 Copyright Statement The author owns the copyright in this thesis, unless stated otherwise. Downloaded from http://hdl.handle.net/10072/365567 Griffith Research Online https://research-repository.griffith.edu.au Griffith University Phytochemical study and anticancer potential of high antioxidant Australian native plants Principal supervisor: Dr Ian Edwin Cock Co-supervisor: Dr Sarah Ashmore By Joseph P Sirdaarta B. Food Science and Nutrition (Hons) School of Natural Sciences Griffith University Submitted in fulfilment of the requirements of the degree of Doctor of Philosophy On the April 11th 2016 Chapter 1 1 | P a g e Statement of Originality This work, entitled Phytochemical study and anticancer potential of high antioxidant Australian native plants, has not previously been submitted for a degree in any university. To the best of my knowledge and belief, the thesis contains no material previously published or written by another person except where due reference is made in the thesis itself. Joseph P Sirdaarta April 11th, 2016 Chapter 1 2 | P a g e Acknowledgements I would like to take this opportunity to thank the Lord Jesus Christ for giving me this opportunity to pursue my PhD. He has all my gratitude for his provisions and support through trying times. Furthermore, I would like to thank Griffith University for offering me the opportunity through scholarships to complete the program. I would like to thank my supervisors Dr Ian Cock and Dr Sarah Ashmore for their help and guidance.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,603.796 B2 Lichter Et Al
    US0096.03796 B2 (12) United States Patent (10) Patent No.: US 9,603.796 B2 Lichter et al. (45) Date of Patent: *Mar. 28, 2017 (54) CONTROLLED RELEASE ANTIMICROBIAL A63L/43 (2006.01) COMPOSITIONS AND METHODS FOR THE A6II 3/522 (2006.01) TREATMENT OF OTC DISORDERS A 6LX 3/573 (2006.01) A63L/7036 (2006.01) (71) Applicants: Otonomy, Inc., San Diego, CA (US); (52) U.S. Cl The R ts of the University of AV e. we (NEON y O CPC .......... A61K 9/0046 (2013.01); A61K 9/0019 s s (2013.01); A61K 9/0024 (2013.01); A61K 9/06 (72) Inventors: Jay Lichter, San Diego, CA (US); (2013.01); A61K 9/10 (2013.01); A61K 9/1641 Andrew M. Trammel, Olathe, KS (2013.01); A61K 31/43 (2013.01); A61 K (US); Fabrice Piu, San Diego, CA 3 1/496 (2013.01); A61 K3I/522 (2013.01); (US); Qiang Ye, San Diego, CA (US); A6 IK3I/573 (2013.01); A61K 3 1/7036 Luis A. Delianary, San Marcos, CA (2013.01); A61K 47/02 (2013.01); A61K 47/10 (US); Carl Lebel Malibu CA (US); (2013.01); A61K 47/34 (2013.01); A6 IK 8/042 Jeffrey P. Harris, La Jolla, CA (US) (2013.01); A61 K 9/14 (2013.01) (58) Field of Classification Search (73) Assignees: OTONOMY, INC., San Diego, CA CPC ... A61K 31/43; A61K 31/496; A61K 31/522; (US): THE REGENTS OF THE A61K 3 1/573; A61K 3 1/7036; A61 K UNIVERSITY OF CALIFORNIA, 47/02: A61K 47/10; A61K 47/34: A61 K Oakland, CA (US) 8/042: A61 K9/0019; A61K 9/0024; A61 K9/0046; A61K 9/06; A61 K9/10: (*) Notice: Subject to any disclaimer, the term of this A61K 9/14: A61 K 9/1641 patent is extended or adjusted under 35 See application file for complete search history.
    [Show full text]
  • Thermotropic Icy Road Sign with Light Scattering and Fluorescence Response
    Thermotropic Icy Road Sign with Light Scattering and Fluorescence Response a a a a Received 8th April 2021, Joshua R. Booth,† Robert A. Young,† Andrés N. Richards Gonzales, Zachary J. Meakin, Corinna M. Preuss-Weber,a,b Ross W. Jaggersa and SteFan A. F. Bon*a Prototypes of flexible, electricity-free, ice warning signs for roads and pavements have been developed. A thermotropic response in the form of an upper critical solution (UCST) type phase separation targeted near the freezing point of water manifests itself through light scattering as a clear-to-opaque transition. It is simultaneously amplified by an enhanced photoluminescence effect. The conceptual road sign application is a multi-lamellar flexible strip with an active layer of a polystyrene-based solution. The solvent is a plasticizer, here either dioctylphthalate (DOP) or its alternative 1,2-cyclohexane dicarboxylic acid diisononyl ester (DINCH). A collection of styrene-based macromolecules were made by free radical (co)polymerization, varying molecular weight and monomer feed composition. UCST type phase diagrams for the polymer solutions were constructed from cloud point data measured by a bespoke photographic set-up, in which up to 30 samples were measured simultaneously using both light scattering, that is opacity, and fluorescence. For the latter, the concept of restricted motion enhanced photoluminescence, often referred to as aggregation-induced emission (AIE), was used. Polystyrene labelled with tetraphenylethylene (TPE) was used for this. The contrast between ‘ON’ and ‘OFF’ states in the protoype ice warning signs was optimized by tuning the polymer concentration and the active layer thickness. Our prototype signs show full reversibility over many temperature cycles.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.433,625 B2 Bosse Et Al
    USOO9433625B2 (12) United States Patent (10) Patent No.: US 9.433,625 B2 BOSse et al. (45) Date of Patent: *Sep. 6, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR (52) U.S. Cl. TREATING OR PREVENTING PAN CPC ........... A61K 3.1/5415 (2013.01); A61K 9/209 - - - (2013.01); A61 K9/2054 (2013.01); A61 K (71) Applicant: 19. Pharma, Inc., Las Vegas, NV 31/167 (2013.01); A61K 31/485 (2013.01) (58) Field of Classification Search (72) Inventors: Paul Bosse, Jupiter, FL (US); John CPC ........... A61K 2300/00; A61K 31/167: A61 K Ameling, Cincinnati, OH (US); 31/485; A61K 3.1/5415: A61 K9/2054; Bernard Schachtel, Jupiter, FL (US); A61 K9/209 Ray Takigiku, Loveland, OH (US) See application file for complete search history. (73) Assignee: LOCL PHARMA, INC., Las Vegas, (56) References Cited NV (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 3,048,526 A 8, 1962 Boswell U.S.C. 154(b) by 0 days. 3,108,046 A 10, 1963 Harbit This patent is Subject to a terminal dis- (Continued) claimer. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/244,455 CA 2262267 A1 8/1999 (22) Filed1C Apr. 3, 2014 DE 102005O13726 A1 9, 2006 pr. 5, (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2014/O3O8349 A1 Oct. 16, 2014 O O U.S. Appl. No. 14/683,886, filed Apr. 10, 2015, Bosse et al. Related U.S. Application Data (Continued) (63) Continuation of application No. 12/967,423, filed on i is: .
    [Show full text]
  • The Barbiturates in Forensic Chemistry Dissertation
    THE BARBITURATES IN FORENSIC CHEMISTRY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy- in the Graduate School of The Ohio State University EQr GWENDOLYN BERTHA CARSON, B« S., M* A* The Ohio State University 195U Approved by* Department of Physiological Chemistry ___________ i TABLE OP CONTENTS page A« Introduction 1 B» Historical 1. The Barbiturates ---------------- 2 2* Barbiturate Poisoning - - -------------------- U a) Deaths due to Barbiturates in Pour Counties and the United States - - ------ ----- 11 b) Doses of Barbiturates in Grains - - -- - - 16 3* Barbiturate Regulations------- - ------------ 21 C. Isolation of the Barbiturates ----- --- - - --- - 2h D» Qualitative Tests for Barbiturates ----- — - ---- 26 E. Quantitative Methods for Barbiturates -------- 28 F* Examination of Tissues --- — 30 1# Degradation Products of Barbiturates ------ 3 1 2a Percent Recovery of Unchanged Barbiturates - - - 3^ G. Experimental Procedures --------------- 35 1* Effect of 5$ Potassium Hydroxide on Barbiturates- 36 2 . Effect of 20$ Acetic Acid on Barbiturates - - - - 38 3. Effect of Water on Salts of Barbituric Acids - - 38 k» Barbiturates Extracted from Liver with 5$ Potassium Hydroxide - — ___ ip. 5. Barbiturates Extracted from Liver with 20$ Acetic A c i d ------------------------------- Hi 6 . Barbiturates Extracted from Liver at pH 1 0 HU 7. Refractive Indices of Barbiturates - ------- H6 8 . Barbiturate-Cyanide Reaction ---------------- 50 9» Effect of Atmospheric Conditions on Barbiturates-
    [Show full text]
  • 2019 BES/Separation Science Research PI Meeting
    TITLE PAGE Program and Abstracts for the 2019 BES/Separation Science Research PI Meeting Gaithersburg Marriott Washingtonian Center 9751 Washingtonian Boulevard Gaithersburg, Maryland, 20878 September 9 – 11, 2019 The research grants and contracts described in this document are supported by the U.S. Department of Energy, Office of Science/Basic Energy Sciences, as part of the Separation Science Program within the Chemical Sciences, Geosciences and Biosciences Division. i FOREWORD This abstract booklet provides a record of the 2019 U.S. Department of Energy (DOE) contractors’ meeting in Separation Science. This meeting, held at the Marriott Washingtonian Hotel in Gaithersburg, Maryland on September 9 – 11, 2019, was sponsored by the Chemical Sciences, Geosciences and Biosciences Division of the Office of Basic Energy Sciences (BES). The purpose of the meeting was to accelerate research progress through collegial interaction. The objectives of the meeting were to develop a common understanding of researchers' activities at the time of the meeting; to maximize potential for collaborative exchange among research groups; to identify the scientific needs of the research community; and to discuss areas for future research directions. The agenda has oral presentations delivered by a number of the Principle Investigators (PIs), as well as an evening poster session. In this way, all PIs within the BES Separation Science Program presented their most recent work that was supported by the program. With ample time for discussion and interactions, this meeting was focused on the exchange of information and building of collaborations; rather than a formal review of researchers’ achievements or a forum to deliberate and choose future directions for the program.
    [Show full text]